Maculopapular Cutaneous Mastocytosis

1. Disease Information

Overview. Maculopapular cutaneous mastocytosis (MPCM), historically termed urticaria pigmentosa (UP), is the most common form of cutaneous mastocytosis (CM). It is defined by an abnormal accumulation of clonal mast cells restricted to the skin, producing multiple hyperpigmented (red‑brown) macules, papules, plaques, or nodules that characteristically urticate (wheal-and-flare) when stroked — the Darier sign. Unlike systemic mastocytosis (SM), the mast-cell infiltrate is confined to the skin with no extracutaneous organ involvement at diagnosis.

According to PubMed, cutaneous mastocytosis "is the most common form in children, is defined when MC infiltration is limited to the skin," and CM "includes three forms: solitary mastocytoma, maculopapular cutaneous mastocytosis (MPCM), and diffuse cutaneous mastocytosis (DCM)" (Giona, Mediterr J Hematol Infect Dis 2021; DOI).

A pivotal 2015 consensus refinement (European Competence Network on Mastocytosis / AAAAI / EAACI) recommended that MPCM be subdivided into two clinically and prognostically distinct variants: - Monomorphic variant — small, uniform maculopapular lesions, typically seen in adults; if it develops in children, it often persists into adulthood and may signal underlying systemic disease. - Polymorphic variant — larger lesions of variable size and shape, typically seen in children; may resolve around puberty.

Verbatim: "we recommend that the typical maculopapular cutaneous lesions (urticaria pigmentosa) should be subdivided into 2 variants, namely a monomorphic variant with small maculopapular lesions, which is typically seen in adult patients, and a polymorphic variant with larger lesions of variable size and shape, which is typically seen in pediatric patients" (Hartmann et al., J Allergy Clin Immunol 2016; DOI). The same consensus removed telangiectasia macularis eruptiva perstans (TMEP) from the CM classification and dropped the adjunct "solitary" from solitary mastocytoma.

Key identifiers | Resource | ID | |---|---| | MONDO | MONDO:0019316 (maculopapular cutaneous mastocytosis) — verified in OLS | | Orphanet | ORPHA:79457 (Maculopapular cutaneous mastocytosis); parent ORPHA:66646 (Cutaneous mastocytosis) | | MeSH | D014582 (Urticaria Pigmentosa) | | SNOMED CT | 1332134000 (Maculopapular cutaneous mastocytosis) | | UMLS/MedGen | C0042111 | | NCIT | C212102 (Urticaria Pigmentosa/MPCM, Monomorphic Variant) | | ICD-10 | Q82.2 (Mastocytosis, congenital/cutaneous); ICD-O 9740/1 for mastocytoma/UP | | ICD-11 | EK90.1 (Cutaneous mastocytosis), with 2A21.0 for indolent SM | | OMIM | 154800 (Mastocytosis, cutaneous; phenotype linked to KIT 164920) |

Synonyms: urticaria pigmentosa (UP); MPCM; UP/MPCM. The terms UP and MPCM are now used interchangeably, with MPCM preferred in modern consensus nomenclature.

Information source. Derived predominantly from aggregated disease-level resources (consensus classifications, systematic reviews, large single-center and registry cohorts) supplemented by individual case reports for rare KIT variants. This is not an EHR-derived entity.

2. Etiology

Primary causal factor — somatic activating KIT mutation. Mastocytosis is a clonal mast-cell disorder driven by gain-of-function mutations in KIT (the receptor for stem cell factor, SCF; CD117). "Genetic aberrations, mainly the KIT D816V mutation, play a crucial role in the pathogenesis of mastocytosis, enhancing MC survival and subsequent accumulation in organs and tissues" (Giona 2021; DOI).

Critical pediatric-vs-adult distinction in the mutational driver. Adults (and systemic disease) are dominated by the canonical activation-loop mutation KIT D816V (exon 17). Children with cutaneous mastocytosis carry a much broader KIT mutation spectrum, frequently outside codon 816, including extracellular/transmembrane (exon 8, 9) and juxtamembrane (exon 11) domain mutations: - "Children with cutaneous mastocytosis typically exhibit mutations in various regions of the KIT gene, whereas those with systemic disease predominantly carry KIT D816V" (Carter, Lange, Hartmann et al., J Allergy Clin Immunol Pract 2025; DOI). - A worked single-case example: a 2-year-old with MPCM carried an Asp419del in exon 8 of KIT (Fukaura et al., Arerugi 2024; DOI). - In the largest pediatric systematic review (1747 cases), "KIT D816V mutation was detected in 34% of 215 tested patients" — i.e., the majority of tested children did not carry D816V (Méni et al., Br J Dermatol 2015; DOI).

Germline / familial forms (rare). Most disease is sporadic/somatic, but rare familial mastocytosis and germline KIT syndromes exist. A germline KIT mutation can produce "GIST cutaneous hyperpigmentation disease" — familial gastrointestinal stromal tumour with cutaneous hyperpigmentation/urticaria pigmentosa (Wali et al., Clin Exp Dermatol 2018; DOI). Familial DCM with specific gene mutations has also been reported (Rydz, Lange et al., Int J Mol Sci 2024; DOI).

Risk factors. - Genetic: somatic KIT activating variants (causal); hereditary alpha-tryptasemia (HαT) — a germline TPSAB1 copy-number gain — is a modifier that raises baseline tryptase and is enriched among SM patients (Beyens et al., Acta Clin Belg 2022; DOI). - Demographic: early childhood onset; modest male predominance (see §9). - Environmental/trigger factors are mast-cell-activation triggers rather than disease-causing: physical stimuli (friction/rubbing, heat, cold, pressure), Hymenoptera stings, certain drugs (opioids, NSAIDs, vancomycin, neuromuscular blockers, radiocontrast), and emotional stress.

Protective factors. No validated genetic or environmental protective alleles are established. The principal "protective" measure is trigger avoidance to reduce mediator-release episodes (Giona 2021; DOI).

Gene–environment interaction. The somatic KIT lesion sets a low threshold for mast-cell degranulation; environmental triggers then precipitate clinical mediator-release symptoms. No quantitative GxE model is documented.

3. Phenotypes

For each phenotype I give type, characteristics, and an HPO lead (to be validated).

Cutaneous (primary, near-universal): - Maculopapular hyperpigmented skin lesions / urticaria pigmentosa (clinical sign; physical manifestation). Red-brown macules/papules, often on trunk and extremities, sparing palms/soles/face in many cases. Frequency: defining (≈75% of pediatric CM present as UP/MPCM — Méni 2015; DOI). HPO leads: Hyperpigmentation of the skin (HP:0000953), Urticaria (HP:0001025). - Darier sign (whealing on stroking a lesion; pathognomonic clinical sign). "Darier's sign was present in 94% of cases" (Kiszewski et al., J Eur Acad Dermatol Venereol 2004; DOI). No dedicated HPO term; can be captured descriptively. - Pruritus (symptom) — the most common mediator symptom, "often triggered by rubbing the lesions" (Giona 2021; DOI). HPO lead: Pruritus (HP:0000989). - Blistering/bullae (sign) — especially in infants/severe polymorphic or diffuse disease. HPO lead: Abnormal blistering of the skin (HP:0008066). - Flushing (sign/symptom) from mediator release. HPO lead: Flushing (HP:0031284). - Dermographism (sign).

Mediator-related systemic symptoms (mast-cell activation, MCA): flushing, pruritus, abdominal pain, diarrhea, headache, hypotension/syncope, and — at the severe end — anaphylaxis. "Many pediatric patients suffer from symptoms of mast cell activation, ranging from pruritus to flushing and blistering" (Carter et al. 2025; DOI). HPO leads: Diarrhea (HP:0002014), Abdominal pain (HP:0002027), Episodic abdominal pain, Hypotension (HP:0002615). Anaphylaxis risk is lower in MPCM than DCM but real, warranting epinephrine auto-injector availability (Giona 2021; DOI).

Laboratory abnormality: elevated serum tryptase (biomarker of mast-cell burden). A basal serum tryptase >20 ng/mL is a minor SM criterion; in pure MPCM tryptase is often normal or mildly elevated, and lower tryptase correlates with the favorable large-lesion variant (Wiechers et al., J Allergy Clin Immunol 2015; DOI).

Phenotype characteristics: - Onset: lesions occur before age 2 in ~90% of pediatric cases (Méni 2015; DOI); "in 92% of cases disease onset was in the first year of life" (Kiszewski 2004; DOI). - Severity: variable — most pediatric MPCM is mild/indolent; severity tracks lesion type (small monomorphic ↔ higher tryptase/persistence). - Progression: often stable then regressing (polymorphic/large-lesion); monomorphic small-lesion disease is more persistent. - Quality of life: impacted by chronic pruritus, cosmetic burden of pigmented lesions, trigger-avoidance lifestyle constraints, and anxiety about anaphylaxis; formal disease-specific QoL instruments (e.g., MC-QoL, MQLQ) exist for mastocytosis but per-phenotype QoL data for pediatric MPCM are limited.

Prognostic phenotype subdivision (important for KB): large lesions = favorable. "Patients with MPCM-large lesions, compared with those with MPCM-small lesions, were characterized by significantly lower tryptase levels, shorter disease duration, and earlier disease onset... more patients with MPCM-large lesions exhibited spontaneous regression" (Wiechers 2015; DOI).

4. Genetic / Molecular Information

Causal gene: KIT (proto-oncogene receptor tyrosine kinase / CD117 / SCF receptor). HGNC hgnc:6342 (dismech lowercase convention); OMIM gene 164920; chromosome 4q12.

Pathogenic variants: - KIT D816V (c.2447A>T, p.Asp816Val; exon 17 activation loop) — the canonical adult/systemic mutation; gain-of-function, constitutive ligand-independent kinase activation. Classified Pathogenic. Somatic. In pediatric CM it is present in only ~one-third of tested cases. - Non-codon-816 KIT variants enriched in pediatric CM: extracellular domain exon 8 (e.g., p.Asp419del), exon 9, and juxtamembrane exon 11 mutations; some are insertions/deletions and missense. A pediatric mature B-cell lymphoma case carried a KIT exon 11 variant (Yazal Erdem et al., J Pediatr Hematol Oncol 2022; DOI). Verbatim exon-8 example: "an Asp419del mutation in exon 8 of the KIT gene" (Fukaura 2024; DOI). - Variant types: missense (dominant), small in-frame deletions, insertions, occasional internal tandem patterns. - Origin: predominantly somatic (lesional skin); rare germline in familial GIST/mastocytosis syndromes. - Functional consequence: gain of function — constitutive KIT autophosphorylation → enhanced mast-cell survival, proliferation, and accumulation. D816V notably confers resistance to imatinib, whereas many non-codon-816 (juxtamembrane/extracellular) variants retain imatinib sensitivity — a therapeutically decisive distinction. - Allele frequency: these are somatic driver mutations; not represented as population germline allele frequencies in gnomAD.

Modifier genes: TPSAB1 (hereditary alpha-tryptasemia) modifies tryptase levels and may modify symptom severity (Beyens 2022; DOI). Additional somatic mutations (TET2, SRSF2, ASXL1 — the "S/A/R" panel) are associated with advanced SM but not typical pediatric MPCM.

Epigenetic / chromosomal: No recurrent epigenetic signature or large-scale chromosomal abnormality is characteristic of MPCM; advanced SM (not MPCM) accrues additional somatic mutations.

5. Environmental Information

MPCM is a clonal genetic disease; environmental factors act as symptom triggers, not causes. Relevant trigger categories: physical (rubbing/friction — the basis of the Darier sign, temperature extremes, pressure), Hymenoptera venom, drugs causing mast-cell degranulation (opioids, NSAIDs, vancomycin, muscle relaxants, iodinated contrast), alcohol (in adults), and emotional/physical stress. Management "is mainly based on strict avoidance of triggers" (Giona 2021; DOI). No infectious agent is implicated.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream): 1. Somatic activating KIT mutation in a mast-cell progenitor (D816V in adults/SM; diverse exon 8/9/11/17 variants in children). 2. → Constitutive, SCF-independent KIT receptor tyrosine kinase activation (autophosphorylation). 3. → Downstream pro-survival/proliferative signaling: PI3K–AKT–mTOR, RAS–RAF–MEK–ERK (MAPK), JAK2–STAT5, and PLCγ cascades. 4. → Enhanced mast-cell survival and clonal accumulation in the dermis (apoptosis resistance + proliferation). 5. → Increased dermal mast-cell density producing the pigmented maculopapular lesions (mast cells stimulate local melanocyte activity → hyperpigmentation). 6. → Mast-cell mediator release (degranulation) on triggering → histamine, tryptase, prostaglandin D2, leukotrienes, heparin, TNF → wheal/flare (Darier sign), pruritus, flushing, blistering, and systemic MCA symptoms up to anaphylaxis.

Molecular pathways (KEGG/Reactome): RTK/KIT signaling; PI3K-AKT; MAPK/ERK; JAK-STAT5. Cellular processes: mast-cell proliferation, apoptosis resistance, and regulated exocytosis/degranulation. Protein dysfunction: gain-of-function KIT with constitutive kinase activity (D816V destabilizes the autoinhibited conformation of the activation loop). Immune involvement: the entire phenotype is mast-cell–mediated (mediator release), without classic autoimmunity or immunodeficiency. Metabolic changes: none disease-specific.

Ontology leads (validate before use): - GO biological process: mast cell degranulation (GO:0043303), mast cell activation (GO:0045576), transmembrane receptor protein tyrosine kinase signaling pathway (GO:0007169), positive regulation of mast cell proliferation, regulation of mast cell apoptotic process. - GO molecular function: stem cell factor receptor activity, protein tyrosine kinase activity (GO:0004713). - CL cell type: mast cell (CL:0000097); consider connective tissue / dermal mast cell subtype. - CHEBI mediators: histamine (CHEBI:18295), prostaglandin D2 (CHEBI:15555).

Molecular profiling. No routine transcriptomic/proteomic/metabolomic signature defines MPCM; diagnosis rests on histology + KIT genotyping + tryptase. Single-cell/spatial work on skin mast cells is emerging but not yet clinically deployed for MPCM.

7. Anatomical Structures Affected

• Organ level — primary: skin (UBERON:0002097, skin of body), specifically the dermis (UBERON:0002067), where mast cells accumulate; the overlying epidermis (UBERON:0001003) shows basal hyperpigmentation.
• Secondary/systemic: by definition absent in CM/MPCM (mast-cell infiltrate limited to skin). Mediator release can transiently affect the GI tract, cardiovascular system (hypotension), and respiratory system during MCA episodes, but there is no organ infiltration.
• Tissue/cell level: connective tissue of the dermis; the targeted cell population is the dermal mast cell (CL:0000097). Lesional biopsies show "a dense accumulation of CD117-positive, round or oval cells with amphophilic cytoplasm within the upper to middle dermis" (Fukaura 2024; DOI).
• Subcellular: mast-cell secretory granules (GO cellular component: secretory granule); plasma-membrane KIT receptor.
• Localization/laterality: lesions are bilateral and disseminated/generalized, typically trunk-predominant; not lateralized.

8. Temporal Development

• Onset: congenital to early infancy; "Lesions occurred before the age of 2 years in 90% of cases" (Méni 2015; DOI); first year of life in ~92% (Kiszewski 2004; DOI). Onset pattern: chronic/insidious.
• Course: generally indolent, often with spontaneous regression around puberty for the pediatric polymorphic/large-lesion variant; "In most children with CM, skin lesions regress spontaneously around puberty; unfortunately, it is not always a self-limiting disease" (Giona 2021; DOI).
• Regression rates (key quantitative data): In a systematic review/meta-analysis, "the complete resolution rate for mastocytoma was 10% per year... while the rate for urticaria pigmentosa was 1.9% per year (95% CI: −0.5%, 4.3%)"; "Diffuse cutaneous mastocytosis and systemic mastocytosis subtypes did not show evidence of complete resolution" (Le et al., Postgrad Med 2017; DOI). In the 1747-case pediatric review, "Clinical regression (complete or partial) occurred in 67% of cases and stabilization in 27%" (Méni 2015; DOI); 80% improved/resolved in the 71-case series (Kiszewski 2004; DOI).
• Adult-onset / monomorphic disease tends to persist lifelong and more often associates with systemic mastocytosis.
• Critical period for prognosis: the monomorphic vs polymorphic distinction at presentation is the key window — monomorphic small lesions in a child flag persistence/possible SM (Hartmann 2016; DOI).

9. Inheritance and Population

• Epidemiology: mastocytosis overall affects roughly 1 in 10,000 people. "Recent studies estimate that 1 in 10,000 people are diagnosed with mastocytosis" (Le 2017; DOI; concordant in Beyens 2022; DOI). MPCM/UP is the most common CM subtype and the most common mastocytosis presentation in children (≈75% of pediatric CM — Méni 2015; DOI).
• Inheritance pattern: predominantly sporadic/somatic (not inherited). Rare familial autosomal-dominant KIT-germline forms exist (Rydz 2024; DOI; Wali 2018; DOI). Penetrance/expressivity, anticipation, founder effects, and carrier frequencies are not applicable to the common somatic disease.
• Sex ratio: modest male predominance — male:female 1.4:1 (Méni 2015; DOI), 1.8:1 (Kiszewski 2004; DOI), and a male-to-female ratio of 2.2 in a 61-patient cohort (Yazal Erdem 2022; DOI).
• Age distribution: strongly bimodal across mastocytosis as a whole — pediatric CM (early childhood, usually <2 yr) vs adult SM; MPCM specifically is the dominant pediatric skin presentation.
• Geographic/ethnic distribution: no strong ethnic predisposition documented; reported worldwide.

10. Diagnostics

Diagnosis is largely clinical and noninvasive in children. "Diagnosis is mainly based on noninvasive measures, including skin inspection, elicitation of the Darier's sign, and analyses of the serum tryptase and KIT variant in blood" (Carter et al. 2025; DOI). "In contrast to adults, mastocytosis in children usually has a benign course making sophisticated or invasive diagnostic tests unnecessary" (Kiszewski 2004; DOI).

• Clinical signs: typical maculopapular lesions + positive Darier sign.
• Laboratory biomarker: serum baseline tryptase (LOINC for tryptase available); >20 ng/mL is a minor SM criterion and prompts evaluation for systemic disease (Valent et al., HemaSphere 2021; DOI).
• Genetic testing: KIT mutation analysis — peripheral-blood allele-specific PCR/ddPCR for D816V; if negative in a child but suspicion remains, lesional-skin KIT sequencing captures non-codon-816 variants (exon 8/9/11). High-sensitivity assays are recommended.
• Histopathology (when biopsy is performed): dermal mast-cell infiltrate, CD117 (KIT) and tryptase-positive on IHC, with aberrant CD25/CD2/CD30 expression supporting clonality. CD30 in MC is now a minor SM criterion (Valent 2021; DOI).
• Bone marrow biopsy: generally avoided in children with typical CM and stable/low tryptase; reserved for adults, persistent monomorphic disease, or red flags suggesting SM. In one cohort "Seven patients were further investigated with suspicion of systemic mastocytosis... none of them developed systemic disease" (Yazal Erdem 2022; DOI).
• Diagnostic criteria framework: WHO / ECNM consensus criteria distinguish CM (mastocytosis in the skin, MIS) from SM (Akin & Valent, Immunol Allergy Clin North Am 2014; DOI; updated consensus Valent 2021; DOI).
• Differential diagnosis: other pigmented/bullous disorders — especially in infants DCM "resemble[s] other bullous skin disorders" (Rydz 2024; DOI); also juvenile xanthogranuloma, post-inflammatory hyperpigmentation, café-au-lait macules/neurofibromatosis, secondary syphilis, and bullous impetigo.
• Screening: no population screening; tryptase + KIT in blood serve as the practical risk-stratification screen for systemic involvement.

11. Outcome / Prognosis

• Overall prognosis is favorable, especially pediatric polymorphic/large-lesion MPCM, with high rates of spontaneous regression (see §8). "Eighty per cent of patients improved or had spontaneous resolution" (Kiszewski 2004; DOI).
• Mortality: low. In the 1747-case pediatric systematic review, "the outcome was fatal in 2.9% of patients" — almost entirely in severe/diffuse or systemic disease, not typical MPCM (Méni 2015; DOI).
• Prognostic factors: lesion morphology (large/polymorphic = favorable, regressing; small/monomorphic = persistent, possible SM), lower baseline tryptase = favorable, earlier onset, shorter disease duration (Wiechers 2015; DOI); KIT genotype (non-D816V child = typical benign CM; persistent D816V/monomorphic = SM risk).
• Morbidity / QoL: chronic pruritus, cosmetic burden, lifestyle restriction from trigger avoidance, and anaphylaxis risk (lower in MPCM than DCM but warranting epinephrine auto-injector provision — Giona 2021; DOI).
• Complications: mediator-release crises/anaphylaxis; blistering in severe infantile disease; rare progression to/coexistence with systemic mastocytosis (mainly monomorphic/adult forms).
• Follow-up: even benign-appearing pediatric cases "require planned follow-up over time" (Giona 2021; DOI).

12. Treatment

Treatment is symptomatic (no curative therapy for CM); it targets mediator symptoms and trigger avoidance.

Trigger avoidance (first-line, all patients) — MAXO lead: therapeutic/preventive avoidance behavior; "strict avoidance of triggers" (Giona 2021; DOI).

Pharmacotherapy (mediator blockade): - H1 antihistamines (first-line for pruritus/flushing) and H2 antihistamines (gastric/GI symptoms). Treatment "with H1 and H2 histamine receptor blockers on demand" is recommended (Giona 2021; DOI). - Mast-cell stabilizer: oral sodium cromoglicate (cromolyn) for GI/cutaneous symptoms; topical corticosteroids for lesions. - Leukotriene receptor antagonists, and aspirin (for prostaglandin-mediated flushing in adults, with caution). - Omalizumab (anti-IgE) for refractory mediator symptoms/recurrent anaphylaxis. Treatment options "encompass avoidance of triggers of mast cell activation, H1 and H2 antihistamines, cromolyn, and omalizumab" (Carter et al. 2025; DOI; see also Castells & Butterfield, J Allergy Clin Immunol Pract 2019; DOI). - Epinephrine auto-injector for anaphylaxis rescue (Giona 2021; DOI).

KIT-targeted / cytoreductive therapy (reserved for systemic or severe disease — not typical MPCM): - Tyrosine kinase inhibitors tailored to the KIT variant. "In children with systemic mastocytosis, tyrosine kinase inhibitors tailored to the specific KIT variant may be considered" (Carter et al. 2025; DOI). Imatinib is effective only for non-D816V / imatinib-sensitive KIT (e.g., juxtamembrane/extracellular variants common in children); D816V is imatinib-resistant, requiring D816V-active inhibitors (midostaurin, avapritinib). Imatinib is among "common choices" for symptomatic systemic disease (Le 2017; DOI). - Phototherapy (PUVA/UVB) for extensive symptomatic skin disease in adults.

Pharmacogenomics: the KIT genotype itself is the decisive "pharmacogenomic" determinant of TKI selection (D816V vs non-D816V).

MAXO leads (validate): pharmacotherapy (NCIT:C15986 for action), antihistamine therapy, immunotherapy/anti-IgE therapy, phototherapy, avoidance behavior; with therapeutic_agent CHEBI/NCIT bindings, e.g., imatinib (CHEBI:45783), omalizumab, midostaurin (NCIT:C1872), avapritinib, cromoglicate, histamine H1 antagonist class.

13. Prevention

No primary prevention exists for this clonal genetic disease. Prevention is effectively tertiary — preventing mediator-release crises and complications: - Trigger avoidance (physical stimuli, culprit drugs, venom) — the central preventive strategy (Giona 2021; DOI). - Premedication (antihistamines ± corticosteroids) before high-risk exposures (surgery/anesthesia, iodinated contrast). - Anaphylaxis preparedness: epinephrine auto-injector and an emergency action plan. - Venom immunotherapy in patients with Hymenoptera-venom anaphylaxis and mastocytosis (more relevant to adults/SM). - Genetic counseling is generally not indicated for sporadic somatic disease but is relevant for the rare germline KIT familial syndromes (Wali 2018; DOI). - Structured follow-up to detect the minority with persistent/systemic disease (Giona 2021; DOI).

14. Other Species / Natural Disease

• Taxonomy/natural disease: Mastocytosis and cutaneous mast-cell tumors occur naturally in animals, most prominently the dog (Canis lupus familiaris, NCBITaxon:9615) — canine mast cell tumors (MCT) are among the most common skin tumors in dogs and frequently carry c-KIT (KIT) mutations (notably exon 11 internal tandem duplications), making them a recognized comparative-oncology model for KIT-driven mast-cell disease. Mast cell tumors also occur in cats (Felis catus, NCBITaxon:9685).
• Orthologous gene: canine KIT (NCBI Gene; ortholog of human KIT).
• Veterinary relevance / comparative pathology: strong — canine MCT KIT biology informed human KIT-targeted therapy; however, canine/feline MCT are typically neoplastic tumors rather than the self-limited pediatric maculopapular pattern, so comparative fidelity to human pediatric MPCM specifically is partial.
• Zoonosis: none — non-transmissible.

Curation note: Veterinary mast-cell-tumor evidence should be tagged evidence_source: MODEL_ORGANISM per dismech rules, and kept distinct from human phenotype support.

15. Model Organisms

• Mouse models: the principal experimental systems. Kit gain-of-function knock-in mice (e.g., Kit D814V, the murine equivalent of human D816V) develop mast-cell hyperplasia/mastocytosis-like disease and have been used to dissect KIT signaling and test TKIs. Kit loss-of-function alleles (W/Wv, KitW-sh "sash") are mast-cell–deficient and are widely used for mast-cell reconstitution studies — important for mast-cell biology though they model deficiency, not mastocytosis. Resource: MGI (gene Kit).
• Cellular / in vitro models: human mast-cell leukemia lines HMC-1 (carries KIT V560G ± D816V) and LAD2; CD34⁺-derived primary human mast cells transfected with mutant KIT; used for KIT-signaling and drug-screening (imatinib-sensitive vs D816V-resistant). Resource: Cellosaurus.
• iPSC / organoid: patient-derived iPSC mast-cell models are emerging but not standardized for MPCM.
• Phenotype recapitulation: KIT gain-of-function models reproduce mast-cell accumulation and constitutive KIT signaling well, and faithfully reproduce D816V imatinib resistance, supporting the molecular mechanism. Limitations: murine models do not reproduce the human pediatric self-limited / pubertal-regression course or the precise human maculopapular cutaneous lesion morphology, and the diverse non-codon-816 pediatric KIT variants are under-modeled.

Curation note (HUMAN_MODEL_MISMATCH candidate): the gap between robust KIT-driven mouse/cell models and the human pediatric spontaneous-regression phenotype is a good kind: HUMAN_MODEL_MISMATCH discussion item — evidence exists in models, but translational validity to the self-limiting pediatric course is the open question.

Consolidated Evidence Table (high-value, snippet-ready)

Suggested dismech entry scaffolding (leads)

• disease_term: MONDO:0019316 (already in draft — confirmed in OLS). Mappings: ORPHA:79457, MeSH:D014582, ICD-10:Q82.2, SNOMED:1332134000, UMLS:C0042111.
• has_subtypes: Monomorphic (small lesions, adult-type, persistent, SM-risk) and Polymorphic (large lesions, pediatric, regressing) — directly supported by Hartmann 2016 / Wiechers 2015. These map cleanly onto prognosis, tryptase, and progression fields.
• Causal gene: gene: KIT (hgnc:6342); pathophysiology node "Constitutive KIT Activation" with modifier: INCREASED, GO:0007169 / GO:0043303, CL:0000097, UBERON:0002067.
• Phenotypes (HP leads): HP:0000953 (hyperpigmentation), HP:0001025 (urticaria), HP:0000989 (pruritus), HP:0031284 (flushing), HP:0008066 (blistering), HP:0002014 (diarrhea) — all to be validated.
• Treatments (MAXO/NCIT leads): trigger avoidance, H1/H2 antihistamines, cromoglicate, omalizumab, epinephrine, KIT-TKI (imatinib for non-D816V; midostaurin/avapritinib for D816V).
• Discussion items: kind: HUMAN_MODEL_MISMATCH for the murine-model vs pediatric-regression gap; kind: KNOWLEDGE_GAP for why non-codon-816 KIT variants associate with the self-limiting pediatric course.

Summary of key, citable facts

MPCM (urticaria pigmentosa) is the most common cutaneous mastocytosis, a clonal KIT-driven dermal mast-cell accumulation presenting in early childhood with hyperpigmented, Darier-positive maculopapular lesions. Children carry diverse KIT variants (often non-D816V) and usually follow a benign, frequently self-resolving course (polymorphic/large-lesion variant), whereas monomorphic small-lesion disease persists and flags possible systemic mastocytosis. Diagnosis is clinical + serum tryptase + KIT genotyping; treatment is symptomatic (trigger avoidance, antihistamines, cromolyn, omalizumab, epinephrine), with KIT-genotype-guided TKIs reserved for systemic/severe disease.

All clinical/mechanistic claims above are sourced from PubMed-indexed literature with DOI links provided inline. Per the dismech anti-hallucination SOP, validate every PMID snippet (just validate-references) and every ontology ID (just validate-terms-file) before committing this content to kb/disorders/Maculopapular_Cutaneous_Mastocytosis.yaml.